Press releases // 11 March 2020
IntegraGen announces the renewal of its partnership agreement with the Institut Pasteur until December 2021 related to high-throughput sequencing operations for microbiology activities carried out at the Institut Pasteur.
Press releases // 12 January 2020
IntegraGen announced today its unaudited business figures for the year 2019.
2019 revenue amounted to 8.3 M € versus 6.9 M € in 2018, an increase of 20% over 12 months. This performance highlights an acceleration from the high growth level of 15% reported for the first half of 2019. (…) »Press releases // 23 September 2019
Press releases // 30 June 2019
The mixed shareholders’ general meeting of IntegraGen was held on Thursday, June 13, 2019 at the Bedford Hotel’s premises at 17 rue de l’Arcade in Paris.
At the end of the Combined General Meeting, (…) »
Press releases // 18 April 2019
IntegraGen has announced the company’s financial results for the year ending December 31, 2018. The annual accounts were approved by the Board of Directors held on April 17, 2019.
Click here to view press release.
Press releases // 15 March 2019
Press releases // 05 March 2019
IntegraGen and Advanced Biological Laboratories (ABL) have announced the signing of a non-exclusive global licensing agreement enabling ABL to distribute miRpredX™, IntegraGen’s proprietary IVD CE marked diagnostic test that enables clinicians to identify metastatic colorectal cancer patients who have a higher likelihood of response to anti-EGFR therapy.
